Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting.

Autor:	Pappalardo A; Medical Oncology Unit, Ospedale del Mare, Naples, Italy.; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy., Giunta EF; Medical Oncology Unit, Ospedale del Mare, Naples, Italy.; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy., Tirino G; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy., Pompella L; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy., Federico P; Medical Oncology Unit, Ospedale del Mare, Naples, Italy., Daniele B; Medical Oncology Unit, Ospedale del Mare, Naples, Italy., De Vita F; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy., Petrillo A; Medical Oncology Unit, Ospedale del Mare, Naples, Italy.; Division of Medical Oncology, Department of Precision Medicine, School of Medicine, University of study of Campania 'L. Vanvitelli', Naples, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in oncology [Front Oncol] 2021 Aug 16; Vol. 11, pp. 695627. Date of Electronic Publication: 2021 Aug 16 (Print Publication: 2021).
DOI:	10.3389/fonc.2021.695627
Abstrakt:	Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease even in the early stages, despite progresses in surgical and pharmacological treatment in recent years. High potential for metastases is the main cause of therapeutic failure in localized disease, highlighting the current limited knowledge of underlying pathological processes. However, nowadays research is focusing on the search for personalized approaches also in the adjuvant setting for PDAC, by implementing the use of biomarkers and investigating new therapeutic targets. In this context, the aim of this narrative review is to summarize the current treatment scenario and new potential therapeutic approaches in early stage PDAC, from both a preclinical and clinical point of view. Additionally, the review examines the role of target therapies in localized PDAC and the influence of neoadjuvant treatments on survival outcomes. Competing Interests: EG had personal fees from Novartis. GT received a travel grant from Servier, Italfarmaco, advisory board: Eli-Lilly. BD received personal fees from Ipsen, Eisai, Eli Lilly, Astra Zeneca, Sanofi, MSD, Bayer, Roche, and Amgen. FV: Scientific consultancy: Servier, Lilly, MSD and BMS; honoraria for speaking: Roche, Bayer, Servier, Lilly, Astellas, MSD and BMS. APe had personal fees with Eli-Lilly, Servier, and MSD. No fees are connected with the submitted paper. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Pappalardo, Giunta, Tirino, Pompella, Federico, Daniele, De Vita and Petrillo.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu